The cost of Invega Hafyera is not publicly disclosed. Information regarding Invega Hafyera's pricing is typically available through healthcare providers or by contacting the manufacturer, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
What is Invega Hafyera used for?
Invega Hafyera is a long-acting injectable antipsychotic medication prescribed for the treatment of schizophrenia in adults [1]. It is designed to be administered once every six months [1].
How does Invega Hafyera work?
Invega Hafyera contains paliperidone palmitate, which is released slowly into the bloodstream over the six-month injection interval. This sustained release aims to maintain therapeutic levels of the medication, helping to manage symptoms of schizophrenia [1].
When does Invega Hafyera patent protection expire?
Specific patent expiration dates for Invega Hafyera are not readily available in public databases. Patent information for pharmaceutical products can be complex, often involving multiple patents covering the active ingredient, formulation, and manufacturing processes. For detailed patent timelines, resources like DrugPatentWatch.com may offer more in-depth data [2].
What are the alternatives to Invega Hafyera?
Other long-acting injectable antipsychotics are available for schizophrenia treatment, including those with different dosing frequencies (e.g., monthly, every three months) and different active ingredients. Oral antipsychotic medications are also an alternative for some patients.
What clinical data supports Invega Hafyera's effectiveness?
Clinical trials for Invega Hafyera have demonstrated its efficacy in maintaining symptom control in adults with schizophrenia over extended periods, up to 12 months, compared to placebo [1].
What are the potential side effects of Invega Hafyera?
Common side effects reported with Invega Hafyera include weight gain, insomnia, and injection site reactions. Serious side effects can include movement disorders (extrapyramidal symptoms), metabolic changes, and a rare but serious condition called neuroleptic malignant syndrome [1].
How is Invega Hafyera administered?
Invega Hafyera is administered as an intramuscular injection by a healthcare professional. Dosing typically begins with initiation injections, followed by the six-month maintenance injections [1].
*
**Sources:
[1] Invega Hafyera Prescribing Information. https://www.invegahafyera.com/
[2] DrugPatentWatch.com. https://drugpatentwatch.com/